Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04EYG
|
||||
| Former ID |
DIB013762
|
||||
| Drug Name |
Ranibizumab
|
||||
| Synonyms |
Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Hereditary hemorrhagic telangiectasia [ICD10:I78.0] | Approved | [1], [2] | ||
| Company |
Genentech Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 1 | Target Info | [3] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| Pathway Interaction Database | Glypican 1 network | ||||
| HIF-2-alpha transcription factor network | |||||
| S1P3 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
| VEGF binds to VEGFR leading to receptor dimerization | |||||
| WikiPathways | Focal Adhesion | ||||
| Signaling by VEGF | |||||
| Angiogenesis | |||||
| References | |||||
| REF 1 | Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006 Sep;19(3):361-72. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6779). | ||||
| REF 3 | Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.